Q-omics provides the consensus-scored SVIL2P profile across patient tissues and cancer cell-line models. SVIL2P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SVIL2P is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SVIL2P RNA expression shows 17,345 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, BLCA, and KIRP as cancer lineages where SVIL2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SVIL2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SVIL2P survival associations across molecular data types. SVIL2P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SVIL2P RNA expression–survival associations across cancer types. High SVIL2P expression shows unfavorable associations in MESO and LGG, but favorable associations in LUAD, HNSC, SKCM and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SVIL2P RNA expression.
This table summarizes SVIL2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SVIL2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SVIL2P shows lower tumor expression in BLCA, UCEC, BRCA, COAD and STAD and higher tumor expression in KIRC. The BLCA box plot shows higher SVIL2P RNA expression in normal versus tumor tissue (log2 FC = −1.216, t-test p = .004).
This table shows molecular features associated with SVIL2P in patient tissues and cancer cell lines. In patient samples, SVIL2P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
